Strata Critical Medical (SRTA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
28 May, 2026Opening remarks and agenda
Meeting opened by outgoing lead independent director, with recognition of departing directors and introduction of new board leadership.
Virtual meeting format explained, with procedures for stockholder questions and rules of conduct outlined.
Introduction of directors, executive officers, and representatives from Deloitte & Touche LLP and Broadridge Financial Solutions.
Board and executive committee updates
Transition in board leadership with the retirement of two directors and nomination of a new lead independent director.
Board composition and roles of executive officers clarified for attendees.
Shareholder proposals
Election of two class 2 directors to serve until the 2029 annual meeting, with board recommendation to vote in favor.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending 31 December 2026.
Advisory vote on executive compensation (say on pay), held annually per prior stockholder guidance.
Latest events from Strata Critical Medical
- Local transplant scale is driving growth, margin gains and more efficient organ recovery.SRTA
UBS Global Healthcare Conference - Q3 growth and record free cash flow supported Clinical-led 2027 targets.SRTA
Q3 2026 - Q3'22 revenue grew 125% YoY as the asset-light platform expanded organ transport and passenger flights.SRTA
Investor presentation - Rapid growth in transplant logistics and perfusion driven by DCD and national expansion.SRTA
2026 Jefferies Healthcare Services and Technology Conference - Q2 2026 revenue up 60.7% year-over-year, with strong growth and margin expansion forecast.SRTA
Investor presentation - Q2 2026 revenue up 60.7% to $72.5M; Adjusted EBITDA and 2026 guidance both increased.SRTA
Q2 2026 - Integrated transplant logistics leader leverages tech, regulatory shifts, and M&A for rapid growth.SRTA
16th Annual East Coast IDEAS Conference - Strong Q1 2026 growth and industry leadership position support continued expansion and profitability.SRTA
Investor presentation - Q2 2024 delivered 11.4% revenue growth, positive Adjusted EBITDA, and record Medical results.SRTA
Q2 2024